These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 16550198)

  • 1. See no evil, hear no evil, do no evil: the lessons of immune privilege.
    Niederkorn JY
    Nat Immunol; 2006 Apr; 7(4):354-9. PubMed ID: 16550198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of Fas ligand in immune privilege.
    Green DR; Ferguson TA
    Nat Rev Mol Cell Biol; 2001 Dec; 2(12):917-24. PubMed ID: 11733771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vision of cell death: Fas ligand and immune privilege 10 years later.
    Ferguson TA; Griffith TS
    Immunol Rev; 2006 Oct; 213():228-38. PubMed ID: 16972907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic changes of apoptosis-inducing ligands and Th1/Th2 like subpopulations in Hantaan virus-induced hemorrhagic fever with renal syndrome.
    Liu JM; Zhu Y; Xu ZW; Ouyang WM; Wang JP; Liu XS; Cao YX; Li Q; Fang L; Zhuang R; Yang AG; Jin BQ
    Clin Immunol; 2006 Jun; 119(3):245-51. PubMed ID: 16616877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune privilege or inflammation? Insights into the Fas ligand enigma.
    O'Connell J; Houston A; Bennett MW; O'Sullivan GC; Shanahan F
    Nat Med; 2001 Mar; 7(3):271-4. PubMed ID: 11231613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. History and physiology of immune privilege.
    Niederkorn JY; Stein-Streilein J
    Ocul Immunol Inflamm; 2010 Jan; 18(1):19-23. PubMed ID: 20128645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunobiology of oligodendrocytes in multiple sclerosis.
    Ruffini F; Chojnacki A; Weiss S; Antel JP
    Adv Neurol; 2006; 98():47-63. PubMed ID: 16400826
    [No Abstract]   [Full Text] [Related]  

  • 8. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
    Huerta-Yepez S; Vega M; Garban H; Bonavida B
    Clin Immunol; 2006 Sep; 120(3):297-309. PubMed ID: 16784892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune privilege in the anterior chamber of the eye.
    Niederkorn JY
    Crit Rev Immunol; 2002; 22(1):13-46. PubMed ID: 12186187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the impact of pro- and antiinflammatory immune processes at the two immune-deviated sites, eye and solid tumor and possible consequences for the antitumoral therapy with fever inducers.
    Schramm H
    Forsch Komplementarmed Klass Naturheilkd; 2005 Feb; 12(1):37-46. PubMed ID: 15772461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune regulation at the interface during early steps of murine implantation: involvement of two new cytokines of the IL-12 family (IL-23 and IL-27) and of TWEAK.
    Mas AE; Petitbarat M; Dubanchet S; Fay S; Ledée N; Chaouat G
    Am J Reprod Immunol; 2008 Apr; 59(4):323-38. PubMed ID: 18336386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Death receptor expression and function at the human blood brain barrier.
    Wosik K; Biernacki K; Khouzam MP; Prat A
    J Neurol Sci; 2007 Aug; 259(1-2):53-60. PubMed ID: 17395209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
    Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
    Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas-ligand and immune privilege: the eyes have it.
    Ferguson TA; Green DR
    Cell Death Differ; 2001 Jul; 8(7):771-2. PubMed ID: 11464222
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response.
    Ferguson TA; Griffith TS
    Chem Immunol Allergy; 2007; 92():140-154. PubMed ID: 17264490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune deviation in relation to ocular immune privilege.
    Streilein JW; Ksander BR; Taylor AW
    J Immunol; 1997 Apr; 158(8):3557-60. PubMed ID: 9103414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers.
    Kassouf N; Thornhill MH
    Oral Oncol; 2008 Jul; 44(7):672-82. PubMed ID: 17996489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of established tumors in mice by a combination antibody-based therapy.
    Uno T; Takeda K; Kojima Y; Yoshizawa H; Akiba H; Mittler RS; Gejyo F; Okumura K; Yagita H; Smyth MJ
    Nat Med; 2006 Jun; 12(6):693-8. PubMed ID: 16680149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why is the fetal allograft not rejected?
    Davies CJ
    J Anim Sci; 2007 Mar; 85(13 Suppl):E32-5. PubMed ID: 17040952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils.
    Cassatella MA
    J Leukoc Biol; 2006 Jun; 79(6):1140-9. PubMed ID: 16574768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.